Fat LossWeight ManagementBody CompositionFat lossPotential joint/cartilage support

RESEARCH REFERENCE

AOD 9604

Modified hGH fragment (176-191) studied for lipolysis without significant IGF-1 elevation.

Quick Reference

Dose: 250–500 mcg
Frequency / schedule: Daily
Route: Subcutaneous
Timing: Morning preferred
Fasting: Best fasted (morning empty stomach)
Cycle: 8–12 weeks
Time off: 4 weeks off
Common vial strengths: 2 mg, 5 mg

How this works

AOD 9604 mimics the lipolytic region of growth hormone. It stimulates fat breakdown via β3-adrenergic pathways without binding the full GH receptor or meaningfully raising IGF-1 or blood glucose.

Benefits + side effects

Potential Benefits

Targeted fat reduction (animal + limited human data)
Minimal impact on IGF-1 or glucose

Side Effects

Mild injection-site reactions
Headache or mild GI (usually similar to placebo in trials)

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Standard	300 mcg	Once daily	Morning fasted	Most common
Higher	500 mcg	Once daily	Morning fasted	Some protocols

Timing + Fasting Notes

Morning on an empty stomach preferred for cleaner lipolytic signaling. Wait 30–60 minutes before eating if possible.

Reconstitution

Common vial strengths2 mg, 5 mg

Approved preparation example
5 mg + 2 mL BAC → 2.5 mg/mL

Practical Reference

Storage: Refrigerated reconstituted
Route / injection context: Subcutaneous
Common vial strengths: 2 mg, 5 mg
Cycle / time off: 8–12 weeks · 4 weeks off
Practical notes: Research use only.

References

Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic healthJournal of Endocrinology and Metabolism · 2013

HUMAN

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric